INTERVENTION 1:	Intervention	0
Empegfilgrastim 6 mg	Intervention	1
Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy	Intervention	2
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.	Intervention	3
solution	CHEBI:75958	149-157
INTERVENTION 2:	Intervention	4
Empegfilgrastim 7.5 mg	Intervention	5
Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy	Intervention	6
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.	Intervention	7
solution	CHEBI:75958	149-157
Inclusion Criteria:	Eligibility	0
Signed informed consent form;	Eligibility	1
Histologically verified diagnosis of stage IIb/III/IV breast cancer;	Eligibility	2
breast cancer	DOID:1612	54-67
Age of 18-70 years inclusive;	Eligibility	3
age	PATO:0000011	0-3
Life expectancy of at least 6 months after inclusion in the study;	Eligibility	4
If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;	Eligibility	5
patient	HADO:0000008,OAE:0001817	7-14
breast cancer	DOID:1612	49-62
ECOG Performance Status of 0- 2, not increasing within during 2 weeks before randomization;	Eligibility	6
ANC level of 1500/μL and more at the beginning of the study	Eligibility	7
Platelet count of 100 000/μL and more at the beginning of the study	Eligibility	8
platelet count	CMO:0000029	0-14
Hemoglobin level of 90 g/l and more	Eligibility	9
hemoglobin	CHEBI:35143	0-10
Creatinine level <1.5 mg/dl	Eligibility	10
creatinine	CHEBI:16737	0-10
Total bilirubin level <1.5 × the upper limit of normal (ULN)	Eligibility	11
ALT and/or AST levels <2.5×ULN (5×ULN for patients with liver metastases);	Eligibility	12
liver	UBERON:0002107	56-61
Alkaline phosphatase <5×ULN;	Eligibility	13
phosphatase	GO:0016791,BAO:0000295	9-20
Left ventricular ejection fraction >50% and more;	Eligibility	14
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin,if in this study planned 6 cycles of chemotherapy ;	Eligibility	15
patient	HADO:0000008,OAE:0001817	7-14
adjuvant	CHEBI:60809	28-36
adjuvant	CHEBI:60809	47-55
doxorubicin	CHEBI:28748,BAO:0000639	135-146
If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for epirubicin,if in this study planned 4 cycles of chemotherapy ;	Eligibility	16
patient	HADO:0000008,OAE:0001817	7-14
adjuvant	CHEBI:60809	28-36
adjuvant	CHEBI:60809	47-55
doxorubicin	CHEBI:28748,BAO:0000639	135-146
Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;	Eligibility	17
Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug;	Eligibility	18
drug	CHEBI:23888	207-211
Patients should be able to follow the Protocol procedures (according to Investigator's assessment.	Eligibility	19
Exclusion Criteria:	Eligibility	20
Patient has received two or more chemotherapy regimens for the metastatic breast cancer;	Eligibility	21
patient	HADO:0000008,OAE:0001817	0-7
breast cancer	DOID:1612	74-87
Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.	Eligibility	22
hypersensitivity	GO:0002524,DOID:1205	11-27
doxorubicin	CHEBI:28748,BAO:0000639	69-80
dexamethasone	CHEBI:41879	82-95
Pregnancy or breastfeeding;	Eligibility	23
Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;	Eligibility	24
Concomitant radiotherapy (except selective radiotherapy of bone metastases);	Eligibility	25
radiotherapy	OAE:0000235	12-24
radiotherapy	OAE:0000235	43-55
Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;	Eligibility	26
surgery	OAE:0000067	0-7
radiotherapy	OAE:0000235	9-21
radiotherapy	OAE:0000235	40-52
History of bone marrow/stem cell transplantation;	Eligibility	27
history	BFO:0000182	0-7
Conditions limiting the patient's ability to follow the protocol;	Eligibility	28
patient	HADO:0000008,OAE:0001817	24-31
CTCAE grade 3-4 neuropathy;	Eligibility	29
neuropathy	DOID:870	16-26
HIV, HCV, HBV, T.Pallidum infection(s);	Eligibility	30
Acute or active chronic infections;	Eligibility	31
acute	HP:0011009,PATO:0000389	0-5
active	PATO:0002354	9-15
chronic	HP:0011010	16-23
Severe concurrent diseases (for example, severe arterial hypertension, severe heart failure, and other);	Eligibility	32
severe	HP:0012828	0-6
severe	HP:0012828	41-47
severe	HP:0012828	71-77
hypertension	HP:0000822,DOID:10763	57-69
heart	UBERON:0000948	78-83
Severe depression, schizophrenia, any other mental disorders;	Eligibility	33
severe	HP:0012828	0-6
depression	HP:0000716	7-17
schizophrenia	HP:0100753,DOID:5419	19-32
Obstacles in intravenous administration of study drugs;	Eligibility	34
Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial.	Eligibility	35
Outcome Measurement:	Results	0
Duration of Neutropenia CTCAE Grade 4	Results	1
duration	PATO:0001309	0-8
neutropenia	HP:0001875,DOID:1227	12-23
The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).	Results	2
efficacy	BAO:0000656	54-62
breast cancer	DOID:1612	148-161
neutropenia	HP:0001875,DOID:1227	198-209
Time frame: 3 weeks	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Empegfilgrastim 6 mg	Results	5
Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy	Results	6
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.	Results	7
solution	CHEBI:75958	149-157
Overall Number of Participants Analyzed: 42	Results	8
Mean (Standard Deviation)	Results	9
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: days  0.905         (1.206)	Results	10
Results 2:	Results	11
Arm/Group Title: Empegfilgrastim 7.5 mg	Results	12
Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy	Results	13
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.	Results	14
solution	CHEBI:75958	149-157
Overall Number of Participants Analyzed: 43	Results	15
Mean (Standard Deviation)	Results	16
mean	BAO:0002173	0-4
standard deviation	BAO:0002176	6-24
Unit of Measure: days  0.791         (1.013)	Results	17
Adverse Events 1:	Adverse Events	0
Total: 1/42 (2.38%)	Adverse Events	1
Febrile neutropenia 0/42 (0.00%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
Agranulocytosis 0/42 (0.00%)	Adverse Events	3
agranulocytosis	HP:0012234,DOID:12987	0-15
nose furunculus 3 grade 0/42 (0.00%)	Adverse Events	4
nose	UBERON:0000004	0-4
Left hand fracture 0/42 (0.00%)	Adverse Events	5
left	HP:0012835	0-4
Uterine bleeding 1/42 (2.38%)	Adverse Events	6
Pneumonia 0/42 (0.00%)	Adverse Events	7
pneumonia	HP:0002090,DOID:552	0-9
Adverse Events 2:	Adverse Events	8
Total: 1/43 (2.33%)	Adverse Events	9
Febrile neutropenia 1/43 (2.33%)	Adverse Events	10
neutropenia	HP:0001875,DOID:1227	8-19
Agranulocytosis 0/43 (0.00%)	Adverse Events	11
agranulocytosis	HP:0012234,DOID:12987	0-15
nose furunculus 3 grade 0/43 (0.00%)	Adverse Events	12
nose	UBERON:0000004	0-4
Left hand fracture 0/43 (0.00%)	Adverse Events	13
left	HP:0012835	0-4
Uterine bleeding 0/43 (0.00%)	Adverse Events	14
Pneumonia 0/43 (0.00%)	Adverse Events	15
pneumonia	HP:0002090,DOID:552	0-9
